Eytan M. Stein, MD, will assume the role of Chief of the Leukemia Service in the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSK), New York. Dr. Stein joined MSK as a medical oncology/hematology fellow in 2010, became a faculty member in 2013, and was appointed the founding Director of the Program for Drug Development in Leukemia in the Division of Hematologic Malignancies in 2019.
Eytan M. Stein, MD
As a clinical researcher, Dr. Stein has a strong track record of developing early-phase clinical trials of novel compounds that target the genetic and epigenetic bases of myeloid malignancies. In 2017, Dr. Stein led a phase I/II clinical trial at MSK to bring the targeted therapy enasidenib—an inhibitor of isocitrate dehydrogenase (IDH)—to people with acute myeloid leukemia (AML) who had an IDH2 mutation. In 2018, he piloted another phase I trial to test ivosidenib, another IDH inhibitor, in patients with advanced IDH1-mutated relapsed or refractory AML. Based on the promising results of both of these investigations, the U.S. Food and Drug Administration approved enasidenib and ivosidenib to treat IDH-mutant AML in 2017 and 2018, respectively.
Dr. Stein also serves as the lead investigator for the BEAT AML master clinical trial. His current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of Menin inhibitors in patients with MLL-rearranged and NPM1-mutant acute leukemias. His work has been published in journals such as Nature, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery, and Blood.